$-0.78
(Market cap
$79,350 Mln
Recently Viewed
Clear AllMarket cap
$79,350 Mln
Revenue (TTM)
$14,343 Mln
P/E Ratio
18.1
P/B Ratio
2.5
Div. Yield
0.5 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$4,505 Mln
ROE
0.1 %
ROCE
13.6 %
Industry P/E
--
EV/EBITDA
12.5
Debt to Equity
0.1
Book Value
$290.8
EPS
$41.9
Face value
--
Shares outstanding
103,902,660
CFO
$28,809.62 Mln
EBITDA
$33,451.99 Mln
Net Profit
$27,518.86 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals (REGN)
| -3.3 | 1.9 | -0.4 | 33.0 | -2.3 | 8.1 | 6.2 |
|
BSE Sensex*
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P 100
| 1.6 | 10.4 | 4.6 | 41.4 | 23.0 | 13.1 | 14.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals (REGN)
| 8.4 | -18.8 | 21.9 | 14.2 | 30.7 | 28.7 | 0.5 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals (REGN)
|
746.6 | 79,350.1 | 14,342.9 | 4,504.9 | 36.8 | 14.9 | 18.1 | 2.5 |
| 310.6 | 41,317.3 | 3,713.9 | 313.8 | 11.2 | 73.3 | 133.5 | 52.4 | |
| 144.5 | 31,186.3 | 606.4 | -1,276.8 | -196.7 | -249.3 | -- | 42.2 | |
| 74.8 | 12,506.7 | 944.0 | -381.0 | -31.6 | -70.7 | -- | 25.6 | |
| 175.2 | 29,945.3 | 16,310.0 | 1,360.0 | 14.2 | 21.6 | 21.9 | 4.4 | |
| 55.6 | 21,304.7 | 1,944.0 | -2,822.0 | -142.4 | -28.9 | -- | 2.5 | |
| 131.2 | 13,402.6 | 2,860.5 | 478.6 | 24.1 | 16.4 | 28.5 | 4.1 | |
| 24.6 | 19,500.6 | 0.0 | -1,079.6 | -- | -206.1 | -- | 29.6 | |
| 574.2 | 25,787.3 | 3,182.7 | 1,334.7 | 54.1 | 19.7 | 21.1 | 3.6 | |
| 437.7 | 112,223.5 | 12,074.6 | 3,953.2 | 38.4 | 22.5 | 28.8 | 5.9 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic,... neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York. Read more
Co-Founder, President, CEO & Co-Chairman
Dr. Leonard S. Schleifer M.D., Ph.D.
Co-Founder, President, CEO & Co-Chairman
Dr. Leonard S. Schleifer M.D., Ph.D.
Headquarters
Tarrytown, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Regeneron Pharmaceuticals Inc (REGN) is $746.58 (NASDAQ) as of 22-Apr-2026 16:12 EDT. Regeneron Pharmaceuticals Inc (REGN) has given a return of -2.31% in the last 3 years.
The P/E ratio of Regeneron Pharmaceuticals Inc (REGN) is 18.08 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.42
|
2.65
|
|
2024
|
18.37
|
2.76
|
|
2023
|
25.31
|
3.85
|
|
2022
|
18.96
|
3.63
|
|
2021
|
8.85
|
3.81
|
The 52-week high and low of Regeneron Pharmaceuticals Inc (REGN) are Rs 821.11 and Rs 476.49 as of 23-Apr-2026.
Regeneron Pharmaceuticals Inc (REGN) has a market capitalisation of $ 79,350 Mln as on 17-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Regeneron Pharmaceuticals Inc (REGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.